Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 40 of 56 for:    severe preeclampsia AND weeks of gestation

A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02336243
Recruitment Status : Unknown
Verified November 2015 by Pontificia Universidad Catolica de Chile.
Recruitment status was:  Recruiting
First Posted : January 12, 2015
Last Update Posted : November 4, 2015
Sponsor:
Collaborators:
University of Chile
Laboratorio Gynopharm - CFR
Information provided by (Responsible Party):
Pontificia Universidad Catolica de Chile

Brief Summary:
This study evaluates the effectiveness of maternal supplementation with Docosahexaenoic acid (DHA) early in pregnancy to reduce the incidence of deep placentation disorders: preterm birth, preterm labor, preterm premature rupture of membranes, preeclampsia and fetal growth restriction. Half of the participants in early pregnancy will receive DHA 600 mg per day, while the other half will receive placebo. Investigators will study also the ability of DHA supplementation, early in pregnancy, to enhance invasion and transformation of spiral arteries by trophoblast, as deep placentation indicators.

Condition or disease Intervention/treatment Phase
Premature Birth Preeclampsia Fetal Growth Retardation Stillbirth Dietary Supplement: Docosahexaenoic acid (DHA) Dietary Supplement: Placebo (for Docosahexaenoic acid (DHA)) Phase 3

Detailed Description:

Introduction: uteroplacental ischemia may cause preterm birth, either due to preterm labor, preterm premature rupture of membranes, or medical indication (in the presence of preeclampsia or fetal growth restriction). Uteroplacental ischemia is the product of defective deep placentation, that is a failure of invasion and transformation of the spiral arteries by the trophoblast. It has been reported that the failure of normal placentation generates a series of clinical abnormalities nowadays called "deep placentation disorders"; they include preeclampsia (PE), fetal growth restriction (FGR), preterm labor (PL), preterm premature rupture of membranes (PPROM), in utero fetal death and placental abruption. Strategies to prevent deep placentation disorders have been just partially effective. Docosahexaenoic acid (DHA) is an essential fatty acid of the family of long chain polyunsaturated fatty acids (LC-PUFAs) or omega-3 fatty acids. Early reports, suggested that a LC-PUFAs rich diet reduces the incidence of deep placentation disorders. Recent randomized controlled trials are inconsistent to show the benefit of DHA supplementation during pregnancy to prevent deep placentation disorders; but most of them showed that DHA supplementation was associated to lower risk of early preterm birth.

Hypothesis: investigators propose that Docosahexaenoic acid (DHA) supplementation, early in pregnancy, reduces the incidence of deep placentation disorders (preterm birth, preterm labor, preterm premature rupture of membranes, preeclampsia and fetal growth restriction), by improving deep placentation physiology: invasion and transformation of spiral arteries by trophoblast.

General Goals: in this proposal investigators aimed to

  1. Assess the effectiveness of maternal supplementation with Docosahexaenoic acid (DHA) early in pregnancy to reduce the incidence of deep placentation disorders: preterm birth, preterm labor, preterm premature rupture of membranes, preeclampsia and fetal growth restriction.
  2. Study the ability of DHA supplementation, early in pregnancy, to enhance invasion and transformation of spiral arteries by trophoblast, as deep placentation indicators. Methodology: investigators will conduct a randomized, placebo controlled, double blind, clinical trial of maternal supplementation with DHA (Docosahexaenoic acid) to prevent deep placentation disorders. Women will be recruited before 16 weeks of pregnancy from 5 ambulatory centers, 2.400 pregnant women will be assigned to 600 mg DHA per day or placebo. A composite outcome will be the primary outcome of the study. The components of the composite outcome will be: preterm birth < 34+0 weeks gestation; early preeclampsia (<34+0 weeks) and severe fetal growth restriction (lower than the 2 percentile and < 34+0 weeks). Each of the outcomes of the composite outcome and other clinically relevant maternal and fetal outcomes will be evaluated as the secondary outcomes of the study. Clinical samples will be obtained from pregnant women on both groups, including: plasma, trophoblast, placental bed and myometrium, to study changes of deep placentation or defective placentation markers. Trophoblast cell lines will be used to study the effect of DHA on trophoblast function in vitro.

Expected outcome: In the randomized clinical trial, a 50% reduction in the incidence of the composite outcome in the DHA group (4% placebo vs. 2% DHA) is expected. Investigators expect to decrease defective deep placentation (placental bed biopsies) and defective placentation markers in DHA supplemented women. Investigators expect also to demonstrate that DHA enhances trophoblast migration and invasion in vitro and decreases production of inflammatory cytokines and anti-vasculogenic mediators.

Relevance: if the findings are positive, DHA supplementation, early in pregnancy, will become a safe and effective strategy for primary prevention of highly relevant pregnancy diseases, such as preterm birth, preeclampsia and fetal growth restriction.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Docosahexaenoic Acid (DHA) Supplementation During Pregnancy to Prevent Deep Placentation Disorders: A Randomized Clinical Trial and a Study of the Molecular Pathways of Abnormal Placentation Prevention
Study Start Date : May 2015
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : April 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Docosahexaenoic acid (DHA)
Docosahexaenoic acid (DHA) 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
Dietary Supplement: Docosahexaenoic acid (DHA)
Docosahexaenoic acid (DHA), 600 mg per day. Each woman will take three DHA capsules per day (200 mg each), as early in gestation as possible and until the end of pregnancy.

Placebo Comparator: Placebo
Placebo 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
Dietary Supplement: Placebo (for Docosahexaenoic acid (DHA))
Each women allocated to the placebo group, will receive three placebo capsules per day. The placebo capsules will have same size, aspect and flavor than the DHA capsules.




Primary Outcome Measures :
  1. Composite outcome: Preterm birth less than 34+0 gestational weeks or preeclampsia before 34+0 gestational weeks or severe fetal growth restrictions early than 34+0 gestational weeks. [ Time Frame: 34 weeks of pregnancy ]
    • Gestational age (first day of the last menstrual period (LMP) or estimated by ultrasound performed before 12+6 weeks of pregnancy).
    • Severe growth restriction defined as birth weight less than the 2nd percentile of population (according to the current national recommended standard).
    • Preeclampsia defined as blood pressure of 140 mm Hg systolic or higher or 90 mm Hg diastolic or higher that occurs after 20 weeks of pregnancy in a woman with previously normal blood pressure and proteinuria (urinary excretion of 0.3 g protein or higher in a 24-hour urine specimen). Or HELLP syndrome (Haemolysis, Elevated, Liver Enzymes, Low Platelets) or superimposed pre-eclampsia, defined as history of pre-existing hypertension (diagnosed pre-pregnancy or before 20+0 weeks' gestation) with new proteinuria. Or Eclampsia, defined as seizures that cannot be attributable to other causes, in a woman with preeclampsia.


Secondary Outcome Measures :
  1. Stillbirth [ Time Frame: During pregnancy ]
    Defined as death of the fetus of at least 500 grams birth weight or, if birth weight is unavailable, a gestational age of at least 20+0 weeks of gestation.

  2. Intrauterine growth restriction [ Time Frame: At delivery ]
    Birth weight less than the 10th percentile of the population standard for the gestational age.

  3. Severe intrauterine growth restriction [ Time Frame: At birth ]
    birth weight less than the 2nd percentile of population (according to the current national recommended standard).

  4. Preterm birth [ Time Frame: At birth ]
    Birth < week 37th, < week 32th, < week 28th

  5. Perinatal death [ Time Frame: From the 20th gestational week to the 28th day of life ]
    number of deaths (fetal deaths and neonatal deaths) of babies ≥500 grams, if birth weight is unavailable, a gestational age ≥20+0 weeks, up to 28 completed days after birth.

  6. Neonatal [ Time Frame: From birth to the 28th day of life ]
    Death of a baby that occurred during the first 28 days of life

  7. Respiratory Distress Syndrome (RDS) [ Time Frame: Until the 28th day of life ]
    Defined as requiring assisted ventilation via endotracheal tube or CPAP (Continuous positive airway pressure) or supplemental oxygen greater or equal to 40% all within the first 24 hours of life and for a duration of greater than or equal to 24 hours, and either an x-ray compatible with RDS or surfactant given between the first 2 and 24 hours of life.

  8. Bronchopulmonary Dysplasia (BPD) [ Time Frame: Until the 28th day of life ]
    Defined as requiring oxygen supplementation at 28 days postnatal age

  9. Intraventricular Hemorrhage (IVH) [ Time Frame: Until the 28th day of life ]

    Diagnosed by imaging, categorized by:

    • Grade 1: blood in germinal matrix
    • Grade 2: blood in germinal matrix and extending into ventricles
    • Grade 3: ventricular enlargement
    • Grade 4: intraparenchymal lesion

  10. Proven Early onset Sepsis [ Time Frame: Within the first 48 hours of life ]
    Within first 48hr of life, confirmed by positive blood or cerebrospinal fluid cultures

  11. Necrotizing Enterocolitis [ Time Frame: Until the 28th day of life ]
    Defined as Bell's stage II (definite case of necrotizing enterocolitis) or greater, or perforation of intestine identified by surgery, or at autopsy. (Neu J. Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Pediatr Clin North Am 1996; 43(2): 409-32.)

  12. Low birth weight [ Time Frame: At birth ]
    Number of Infants with a birth weight < 1500 grams, number of Infants with a birth weight < 2500 grams

  13. Admitted to Neonatal Intensive Care Unit (NICU) [ Time Frame: Until the 28th day of life ]
  14. Birth biometry [ Time Frame: At birth ]
    Measurement of ponderal index (birth weight/height^3×100), head circumference (cm), Birth weight (grams).

  15. Cesarean section [ Time Frame: At delivery ]
    Number of deliveries by cesarean section

  16. Preeclampsia [ Time Frame: From pregnancy to discharge after delivery ]
    Defined as blood pressure of 140 mm Hg systolic or higher or 90 mm Hg diastolic or higher that occurs after 20 weeks of pregnancy in a woman with previously normal blood pressure and proteinuria, defined as urinary excretion of 0.3 g protein or higher in a 24-hour urine specimen. Or HELLP (Haemolysis, Elevated, Liver Enzymes, Low Platelets) syndrome Or Superimposed pre-eclampsia, defined as history of pre-existing hypertension (diagnosed pre- pregnancy or before 20+0 weeks' gestation) with new proteinuria. Or Eclampsia, defined as seizures that cannot be attributable to other causes, in a woman with preeclampsia.

  17. Gestational Diabetes (GDM) [ Time Frame: During pregnancy ]
    Screening during pregnancy

  18. Premature rupture of membranes [ Time Frame: During pregnancy ]
    Rupture of the amniotic sac before the onset of labor

  19. Maternal Venous Thrombosis [ Time Frame: During pregnancy ]
    Venous Thrombosis confirmed by imaging during pregnancy

  20. Bleeding during pregnancy [ Time Frame: During pregnancy ]
    Genital bleeding diagnosed during pregnancy

  21. Placental Abruptio [ Time Frame: During pregnancy ]
    Prematurely detachment of a normal positioned placenta for the wall of uterus

  22. Postpartum bleeding [ Time Frame: Postpartum period ]
    Estimated bleeding more than 500 ml after vaginal birth or 1000 ml after cesarean section

  23. Postpartum depression [ Time Frame: At the 6th postpartum week ]
    Postpartum Depression defined by the Edinburgh Postnatal Depression Scale (EPDS)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Women 18 years old or older at time of consent
  • Capability of the subject to comprehend and comply with study requirements
  • Live embryo or fetus (documented with positive fetal heart rate prior randomisation)
  • Gestational age before 16+0 weeks of pregnancy
  • Planning to deliver at Hospital Dr. Sótero del Río, Hospital Padre Hurtado, or Hospital Clínico Universidad Católica de Chile.

Exclusion Criteria:

  • Preexisting diabetes mellitus.
  • Uterine anatomic malformation (bicornuate, septate uterus).
  • Already taking a prenatal supplement with DHA.
  • Bleeding disorder in which DHA was contraindicated.
  • Anticoagulant therapy.
  • Documented history of drug or alcohol abuse.
  • Embryo or Fetus with a known mayor abnormality.
  • Unable to give written informed consent.
  • In the judgment of the investigator, will be unwilling or unable to comply with study protocol.
  • Currently participating in another fatty acid trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02336243


Contacts
Layout table for location contacts
Contact: Jorge Carvajal, PhD +56 223543409 jcarva@med.puc.cl

Locations
Layout table for location information
Chile
Centro de Salud Familiar ANCORA Juan Pablo II Recruiting
Santiago, Chile
Contact: Francisco Arancibia, Matron         
Contact    +56 2 2482 2400      
Centro de Salud Familiar ANCORA Madre Teresa de Calcuta Recruiting
Santiago, Chile
Contact: Patricia Alar, Enf Matrona         
Contact    +56 2 2851 5211      
Centro de Salud Familiar ANCORA San Alberto Hurtado Recruiting
Santiago, Chile
Contact: Ghislaine Bustamante, Matrona         
Contact    +56 2 2587 9300      
Centro Medico Lira 85 Recruiting
Santiago, Chile
Contact: Cecilia Berrios, Enf Matrona         
Contact    +56 2 2354 8077      
Centro Medico San Joaquin Recruiting
Santiago, Chile
Contact: Veronica Nuñez, Enf Matrona         
Contact    +56 2 2354 8540      
Sponsors and Collaborators
Pontificia Universidad Catolica de Chile
University of Chile
Laboratorio Gynopharm - CFR
Investigators
Layout table for investigator information
Principal Investigator: Jorge Carvajal, PhD Pontificia Universidad Catolica de Chile
Study Director: Claudio Vera, MSc Pontificia Universidad Catolica de Chile
Study Director: Paulina Rojas, MD Pontificia Universidad Catolica de Chile
Study Director: Paola Casanello, PhD Pontificia Universidad Catolica de Chile
Study Director: Mauro Parra, MD University of Chile
Study Director: Christian Figueroa, MD Pontificia Universidad Catolica de Chile
Study Director: Sergio González, MD Pontificia Universidad Catolica de Chile

Layout table for additonal information
Responsible Party: Pontificia Universidad Catolica de Chile
ClinicalTrials.gov Identifier: NCT02336243     History of Changes
Other Study ID Numbers: 13-217
1141207 ( Other Grant/Funding Number: FONDECYT )
First Posted: January 12, 2015    Key Record Dates
Last Update Posted: November 4, 2015
Last Verified: November 2015
Keywords provided by Pontificia Universidad Catolica de Chile:
docosahexaenoic acid
premature birth
placentation disorders
preeclampsia
fetal growth
Additional relevant MeSH terms:
Layout table for MeSH terms
Pre-Eclampsia
Pregnancy Complications
Hypertension, Pregnancy-Induced
Premature Birth
Stillbirth
Fetal Growth Retardation
Obstetric Labor, Premature
Obstetric Labor Complications
Fetal Death
Death
Pathologic Processes
Fetal Diseases
Growth Disorders